{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"40.0"},{"groupId":"OG002","value":"50.0"},{"groupId":"OG003","value":"45.0"}]}],"title":"SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100."},{"groupId":"OG001","value":"95.0"},{"groupId":"OG002","value":"94.4"},{"groupId":"OG003","value":"100."}]}],"title":"TEAS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after a participant provides informed consent. A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Serious adverse event (SAE) is defined as an event that meets 1 of the following criteria: is fatal or life threatening, results in persistent or significant disability or incapacity, constitutes a congenital anomaly or birth defect, is clinically meaningful (i.e. defined as an event that jeopardizes the participant or requires potential medical or surgical intervention to prevent 1 of the outcomes listed above) or requires inpatient hospitalization or prolongation of existing hospitalization.","groups":[{"description":"Epacadostat 25 mg tablet orally twice daily (BID) starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG000","title":"Phase 1: Epacadostat 25 mg BID"},{"description":"Epacadostat 50 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG001","title":"Phase 1: Epacadostat 50 mg BID"},{"description":"Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG002","title":"Phase 1: Epacadostat 100 mg BID"},{"description":"Epacadostat 300 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG003","title":"Phase 1: Epacadostat 300 mg BID"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab).","reportingStatus":"POSTED","timeFrame":"Approximately 54 months","title":"Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}